FI3638277T3 - Koostumukset ja menetelmät beetasekretaasin estämiseksi - Google Patents

Koostumukset ja menetelmät beetasekretaasin estämiseksi Download PDF

Info

Publication number
FI3638277T3
FI3638277T3 FIEP18816475.0T FI18816475T FI3638277T3 FI 3638277 T3 FI3638277 T3 FI 3638277T3 FI 18816475 T FI18816475 T FI 18816475T FI 3638277 T3 FI3638277 T3 FI 3638277T3
Authority
FI
Finland
Prior art keywords
weight
composition
oroxylin
chrysin
baicalein
Prior art date
Application number
FIEP18816475.0T
Other languages
English (en)
Finnish (fi)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Original Assignee
Sami Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Labs Ltd filed Critical Sami Labs Ltd
Application granted granted Critical
Publication of FI3638277T3 publication Critical patent/FI3638277T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP18816475.0T 2017-06-15 2018-06-14 Koostumukset ja menetelmät beetasekretaasin estämiseksi FI3638277T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (1)

Publication Number Publication Date
FI3638277T3 true FI3638277T3 (fi) 2025-01-10

Family

ID=64655980

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18816475.0T FI3638277T3 (fi) 2017-06-15 2018-06-14 Koostumukset ja menetelmät beetasekretaasin estämiseksi

Country Status (9)

Country Link
US (2) US11458117B2 (https=)
EP (2) EP3638277B1 (https=)
JP (2) JP7209645B2 (https=)
KR (2) KR20190134809A (https=)
CA (2) CA3063751C (https=)
ES (1) ES3005508T3 (https=)
FI (1) FI3638277T3 (https=)
PL (2) PL3638277T3 (https=)
WO (2) WO2018232063A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3005508T3 (en) * 2017-06-15 2025-03-14 Sami Labs Ltd Compositions and methods for beta secretase inhibition
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
CN114630650B (zh) * 2019-08-26 2024-03-29 萨米-萨宾莎集团有限公司 植物活性物及其防污染效果
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837003B (zh) * 2002-04-30 2013-09-04 尤尼根公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
MXPA06002456A (es) * 2003-09-02 2006-08-31 Unigen Pharmaceuticals Inc Formulacion de una mezcla de flavonoides con el aniillo b libre y flavanos para utilizarse en la prevencion y tratamiento de la declinacion cognoscitiva y el deterioro de la memoria relacionado con la edad.
US7855200B2 (en) * 2006-01-09 2010-12-21 Council Of Scientific And Industrial Research Method for treatment of gastric ulcers and ulcers induced by aspirin
JP2009527541A (ja) 2006-02-21 2009-07-30 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 腸管αグルコシダーゼ阻害剤ならびにその単離方法およびその使用
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 a를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
US20150231067A1 (en) * 2012-08-29 2015-08-20 Mannkind Corporation Method and composition for treating hyperglycemia
NZ753943A (en) * 2016-11-11 2021-03-26 Sami Labs Ltd Composition containing oroxylin a and method of extraction thereof
ES3005508T3 (en) 2017-06-15 2025-03-14 Sami Labs Ltd Compositions and methods for beta secretase inhibition

Also Published As

Publication number Publication date
WO2018232063A1 (en) 2018-12-20
EP3638278B1 (en) 2022-05-11
EP3638278A4 (en) 2021-03-17
US20180360800A1 (en) 2018-12-20
US11458117B2 (en) 2022-10-04
EP3638277A1 (en) 2020-04-22
ES3005508T3 (en) 2025-03-14
EP3638277A4 (en) 2021-03-17
WO2018232224A1 (en) 2018-12-20
CA3063751A1 (en) 2018-12-20
CA3063757C (en) 2023-08-01
KR20190134809A (ko) 2019-12-04
PL3638278T3 (pl) 2022-10-03
EP3638277B1 (en) 2024-10-09
US20180360801A1 (en) 2018-12-20
JP7209645B2 (ja) 2023-01-20
US10894029B2 (en) 2021-01-19
EP3638278A1 (en) 2020-04-22
JP2020523342A (ja) 2020-08-06
KR20190131589A (ko) 2019-11-26
JP6796217B2 (ja) 2020-12-02
PL3638277T3 (pl) 2025-03-10
JP2020523372A (ja) 2020-08-06
CA3063757A1 (en) 2018-12-20
CA3063751C (en) 2023-01-03

Similar Documents

Publication Publication Date Title
FI3638277T3 (fi) Koostumukset ja menetelmät beetasekretaasin estämiseksi
AU2021206784B2 (en) Combinations of cannabinoids and N-acylethanolamines
FI4061344T3 (fi) 6-hydroksikannabidioli käytettäväksi lääkkeenä
MX2022007276A (es) Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas.
NO20063693L (no) Forbindelse og metode for anvendelse
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
JP2020523342A5 (https=)
CO2022000657A2 (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
RU2014122858A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями
Kurata et al. Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain
AR064740A1 (es) Compuesto de [1,2,3] -benzotriazinona-3-sustituido para mejorar las respuestas sinapticas glutamatergicas
WO2019205748A1 (zh) 一种化合物在抑制A β蛋白聚积治疗老年痴呆方面的应用
AU2017261303A1 (en) Ophthalmic compositions
JPWO2021099775A5 (https=)
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
CN104523679A (zh) 青蒿琥酯在制备治疗、预防中枢神经损伤药物中的应用
JP2014224108A5 (https=)
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
NO20090814L (no) N-fenyl-prenylamin derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser
CN104224808B (zh) 米诺环素用于妊娠期间应激所致的后代神经精神损伤的保护作用
WO2011061554A8 (en) Pharmaceutical composition for the treatment of bladder disorders
EP2905017B1 (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cerebrovascular disease and neurodegenerative diseases of the central nervous system
RU2017135273A (ru) Пирролидон-карбоновая кислота (рса) для офтальмологического применения
US20170333450A1 (en) Compositions and methods for treating hiv-associated cognitive dysfunction